| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H20O4 |
| Molecular Weight | 348.3918 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(O)C=CC2=C1OC[C@H]([C@H]2C3=CC=C(O)C=C3)C4=CC=C(O)C=C4
InChI
InChIKey=QVCAATSEPLQVBX-FPOVZHCZSA-N
InChI=1S/C22H20O4/c1-13-20(25)11-10-18-21(15-4-8-17(24)9-5-15)19(12-26-22(13)18)14-2-6-16(23)7-3-14/h2-11,19,21,23-25H,12H2,1H3/t19-,21-/m0/s1
| Molecular Formula | C22H20O4 |
| Molecular Weight | 348.3918 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
ME-344 is an isoflavone-derived antineoplastic agent. ME-344 is an active metabolite of NV-128. ME-344 exerts antitumor activity through inhibiting mitochondrial NADH: ubiquinone oxidoreductase (Complex I) and inducing caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. ME-344 inhibited tubulin polymerization by interacting with tubulin near the colchicine-binding site. Furthermore, inhibition of tubulin polymerization was functionally important for ME-344 induced death. ME-344 is being developed for the treatment of solid tumors.